Nitroxoline Cysteine Protease Inhibitors for Selective Coronavirus Blocking
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for coronavirus diseases, particularly those caused by SARS-CoV-2, are inadequate in effectively inhibiting viral entry and replication due to the involvement of cathepsin B and B-like proteases, with existing inhibitors showing partial efficacy or off-target effects.
Innovation Solution
The use of 8-hydroxyquinoline cysteine protease inhibitors, specifically Nitroxoline and Compound 17, which are potent reversible inhibitors of cathepsin B, to block viral entry and replication by synergistic cathepsin B inhibition and metal ion chelation, offering superior efficacy over other inhibitors.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If small molecule compounds are used as antiviral agents, then they can penetrate cell membranes and inhibit viral replication, but they may also inhibit host cell proteases and cause adverse effects
Solution Approach 1:
The patent applies local quality by designing the 8-hydroxyquinoline core structure with specific substituents at defined positions (R1, R2, R3, R4, R5, R6, R7, R8) to create differential binding affinity. The molecular structure is optimized to fit specifically into the main protease active site while avoiding key interactions with host cell proteases, thereby achieving selective inhibition that preserves host cell function while blocking viral replication.
Solution Approach 2:
The patent employs parameter changes by systematically varying the substituent groups on the 8-hydroxyquinoline core structure to optimize the balance between viral protease inhibition and host cell protease sparing. By modifying parameters such as substituent type, position, and electronic properties, the invention tunes the compound's selectivity profile to achieve potent antiviral activity with reduced host cell toxicity.
2Reliability
If conventional antiviral screening methods are used, then viral replication inhibition can be identified, but the risk of host cell toxicity and false positives increases
Solution Approach 1:
The patent applies preliminary action by conducting a comprehensive in silico screening campaign before experimental validation. Virtual screening of compound libraries against the main protease structure allows pre-selection of candidates with favorable selectivity profiles, filtering out compounds likely to cause host cell toxicity before they reach experimental testing stages. This preliminary computational filtering reduces false positives and improves the safety profile of candidates advancing to wet-lab validation.
Data Source
Figure 1
Figure 1
AI summary
The present invention generally relates to 8-hydroxyquinoline cysteine protease inhibitors, and more specifically to 5-nitro-8-hydroxyquinoline (nitroxoline) and derivatives thereof, for use in the prevention and/or treatment of a disease caused by a virus of the coronavirus subfamily, and in particular of a disease caused by the virus SARS-CoV-2.